Lessons and open questions in borderline resectable pancreatic cancer
- PMID: 36521503
- DOI: 10.1016/S2468-1253(22)00393-4
Lessons and open questions in borderline resectable pancreatic cancer
Conflict of interest statement
MR reports advisory board membership for AstraZeneca, Panvance, Viatris, Sotio, Servier, Merck Sharp and Dohme, Baxter, and Celgene; research grants from AstraZeneca, Celgene, and Merck Sharp and Dohme; and financial support to the Italian Association for the Study of the Pancreas, as part of the steering committee. GO declares no competing interests.
Comment on
-
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521500 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
